The Impact of Urine-Sample HPV Testing on the Effectiveness of Screening for Cervical Cancer: An Umbrella Review
Miazga et al.
The finding, in our words
First-void urine testing detected HPV with 87% sensitivity and 89% specificity, and participants reported feeling comfortable with this self-collection method. This approach could improve uptake of cervical cancer screening in decentralised settings.
A paraphrase to the Library’s standard, never the abstract. The source is one link away and is always the authority.
Urine-based HPV testing demonstrated 74% sensitivity and 52% specificity for detecting CIN2+, with performance improving when first-void collection and PCR-based assays were used. Although less sensitive than clinician-collected cervical samples, urine testing was preferred by over 90% of women, indicating potential as a complementary screening strategy to improve uptake.
A systematic review of 70 studies found that 94.7% of accuracy studies reported comparable sensitivity and specificity between self-sampling and clinician collection for HPV detection, with patient acceptability ranging from 84.2% to 100% for devices including Colli-Pee. This evidence endorses decentralised cervical screening to improve uptake.
First-void urine self-collection for HPV testing showed good agreement with cervical samples using the COBAS assay (kappa 0.66) but only moderate agreement with CLART (kappa 0.47). The COBAS assay achieved 63.9% sensitivity and 96.5% specificity with far fewer invalid results than CLART (1.8% versus 26.9%), and 42% of women preferred urine sampling, indicating that urine-based HPV testing is an acceptable decentralised option but requires improved analytical performance before implementation for non-participants.
This meta-analysis found that HPV testing using self-collected vaginal and urine samples showed sensitivities of 88.6% and 81% for detecting cervical precancer. Using a standardised device for first-void urine increased sensitivity to 86.6%, supporting decentralised patient-centric screening, though data on specificity and specific commercial devices were not consistently reported.
A study of 2500 women found 99.0% agreement between first-void urine and vaginal self-sampling for HPV detection using Cobas4800, with 98.1% of participants preferring urine. Although conducted in a resource-limited setting which may limit generalisability, these results support urine as a viable sample type for decentralised, patient-centric screening.